Adverse reactions to radiopharmaceuticals are still not reported worldwide. However, the type of reaction may be severe and cause death. A review of the literature was performed using some criteria of a systematic review established by the Cochrane Collaboration. The results showed that there are a large number of adverse reactions to radiopharmaceuticals. Nuclear medicine staff must be aware of the possibility of adverse reaction with radiopharmaceuticals and find time to share this information with the radiopharmacist and the national pharmacovigilance system.
LazarouJPomeranzBHCoreyPN. Incidence of adverse drug reactions in hospitalized patients—a meta-analysis of prospective studies. JAMA. 1998;279(15):1200–1204.
2.
ShepherdGMohornPYacoubK. Adverse drug reaction deaths reported in United States vital statistics, 1999–2006. Ann Pharmacother. 2012;46:169–75.
3.
PirmohamedMJamesSMeakinS. Adverse drug reaction as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ2004;329:15–19.
4.
LarocheMLQuevelenIMazereJMerleL. Adverse reaction to radiopharmaceuticals in France: analysis of the national pharmacovigilance database. Ann Pharmacother. 2015;49(1):39–47.
5.
JonesJK. Adverse drug reactions in the community health setting: approaches to recognizing, counseling, and reporting. Fam Community Health. 1982;5:58–67.
6.
SampsonCB. Adverse reactions and drug interactions with radiopharmaceuticals. Drug Safety. 1993;8(4):280–294.
7.
ScottJR.Canadian Adverse Reaction Reporting Program for Radiopharmaceuticals Summary, January 1989–January 1991. Bulletin 7, spring edition. Ottawa, Canada, Society of Nuclear Medicine of Canada; 1997.
8.
SilbersteinEBRyanJ. Prevalence of adverse reactions in nuclear medicine. J Nucl Med. 1996;37(1):185–192.
9.
HesselwoodSRKeelingDH. Frequency of adverse reactions to radiopharmaceuticals in Europe. Eur J Nucl Med. 1997;24(9):1179–1182.
10.
NyakaleLLockhatZSathekgeMM. Nuclear medicine–induced allergic reaction. Curr All Clin Immunol. 2015;28(1):10:17
11.
SilbersteinEB. Prevalence of adverse reactions to positron emitting radiopharmaceuticals in nuclear medicine. J Nucl Med. 1998;39(12):2190–2192.
12.
LokeYKPriceDHerxheimerA; Cochrane Adverse Effects Methods Group. Systematic reviews of adverse effects: framework for structural approach. BMC Med Res Methodol. 2007;7:32
13.
HladikWBNiggKKRhodesBA. Drug-induced changes in the biological distribution of radiopharmaceuticals. Semin Nucl Med. 1982;2:184–218.
CordovaMAHladikWBRhodesBA. Validation and characterization of adverse reactions to radiopharmaceuticals. Noninv Med Imag. 1984;1:17–24.
16.
SilbersteinEBRyanJ. Prevalence of adverse reactions in nuclear medicine. Pharmacopeia Committee of the Society of Nuclear Medicine. J Nucl Med. 1996:37(6):185–192.
17.
BalanKKChoudharyAKBalanAWishartG. Severe systemic reaction to (99m)Tc-methylene diphosphonate: a case report. J Nucl Med Tech. 2003;31(2):76–78.
18.
ChickenDWMansourREllPJKeshtgarMRS. Allergy to technetium-labelled nanocolloidal albumin for sentinel node identification. Ann R Coll Surg Engl. 2007;89:1–2.
19.
MujtabaBAdenaikeMYagantiVMujtabaNJainD. Anaphylactic reaction to Tc-99m sestamibi (Cardiolite) during pharmacologic myocardial perfusion imaging. J Nucl Cardiol. 2007;14(2):256–258.
20.
ThomsonLEAllmanKC. Erythema multiforme reaction to sestamibi. J Nucl Med. 2001;42:534.
21.
MaedaJOhtaMHirabayashiHMatsudaH. False positive accumulation in 18F fluorodeoxyglucose positron emission tomography scan due to sarcoid reaction following induction chemotherapy for lung cancer. Jpn J Thorac Cardiovasc Surg. 2005;53(4):196–198.
22.
WeberWAPetersenVSchimdtB. Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. J Clin Oncol. 2003;21:2651–2657.
23.
LindsayMJSiegelBATunisSR. The National Oncologic PET Registry: Expanded Medicare Coverage for PET under coverage with evidence development. AJR Am J Roentgenol. 2007;188:1109–113.
24.
ReillyTBSchusterDMStarsiakMD. Sarcoid-like reaction in the spleen following chemotherapy for non-Hodgkin’s lymphoma. Clin Nucl Med. 2007;32(7):569–571.
25.
HanEJParkHLKimSH. Allergic Reaction to ginkgo nut on FDG PET/CT. Clin Nucl Med. 2016;41(
9
):716–717.
26.
GalettaDBellomiMGranaC. Radio-guided localization and resection of small or ill-defined pulmonary lesions. Ann Thorac Surg. 2015;100(
4
):1175–1180.
27.
IwasakiTKakagawaKKtsuraH. Pulmonary suture abscess with false-positive 18-F-fluorodeoxyglucose positron emission scan mimicking lung cancer recurrence. Jpn J Thorac Cardiovasc Surg. 2006;54:351–355.
28.
AideNDeuxJFPerettiI. Persistent foreign body reaction around inguinal mesh prostheses: a potential pitfall of FDG pet. AJR Am J Roentgenol. 2005;184:1172–1177.
29.
HurwitzR. F-18 FDG positron emission tomographic imaging in a case of ruptured breast implant: inflammation or recurrent tumor?Clin Nucl Med. 2003;28(9):755–756.
30.
ModiDFulhamMJMohamedA. Markedly increased FDG uptake in a vocal cord after medialization with Teflon: PET/CT findings. Clin Nucl Med. 2005;30(1):45–47.
31.
ZhuangHChackoTKHickesonM. Persistent non-specific FDG uptake on PET imaging following hip arthroplasty. Eur J Nucl Med. 2002;29(10):1328–1333.
32.
ChismCBSomcioRChasenBA. Increased 18F-FDG uptake associated with gastric banding surgical mesh on PET/CT. Clin Nucl Med. 2016;41(
5
):410–411.
33.
KusakabeKOkamuraTKasagiK; Subcommittee for Safety Issues of Radiopharmaceuticals, Medical Science; Pharmaceutical Committee, Japan Radioisotope Association. 27th Report on Survey of Adverse Reaction to Radiopharmaceutical (The 30th survey in 2004). Kaku Igaku. 2006;43(1):23–25.
